Company Overview

Oligovax SAS is a privately held biopharmaceutical company dedicated to the development of anti-cancer medicines belonging to a new therapeutic class, Tool Like Receptor 9 (TLR9) agonists.

The company was created in 2000, based on the research of Professor Antoine F. Carpentier who co-founded the company with Paul van der Schueren.

The company's technology approach is based on drug substances consisting of synthetic oligonucleotides (ODNs) containing CpG motifs that have optimized immunostimulating properties. The CpG-ODN "Litenimod" developed by the company is a very powerful Th1 adjuvant when combined with a broad range of antigens, leading to both cytotoxic T lymphocytes (CTL) and antibody immune response.


Oligovax SAS
102 avenue des Champs Elysťes
75008 Paris

© Copyright Oligovax 2018 - All Rights Reserved
Mentions légales : Site et contenus propriétés d'Oligovax
Création et intégration : Justine Gélis / - Hébergeur OVH